Patents Assigned to K.U. Leuven Research & Development
  • Patent number: 10407623
    Abstract: The disclosure describes a one-step liquid biphasic catalytic process for converting a carbohydrate-containing feedstock, preferably lignocellulose, to light naphtha (e.g., hexane, pentane, methyl cyclopentane, cyclohexane, etc.) in the presence of an acidic reactive aqueous phase and a redox catalyst in the organic extracting/reaction phase. The process provides a cost-effective route for producing light-naphtha components, in presence or not of deoxygenates. The light naphtha components are useful as feedstock for steam and catalytic cracking to produce value-added platform molecules like ethylene and propylene, as precursor for the synthesis of bioaromatics like benzene and as gasoline fuel feedstock, and as fuel additives (e.g., the concomitantly formed oxygenates) to improve the biological origin of carbon in the fuel.
    Type: Grant
    Filed: May 12, 2015
    Date of Patent: September 10, 2019
    Assignee: Katholieke Universiteit Leuven, K.U. Leuven Research & Development
    Inventors: Michiel Julien Dusselier, Beau Op De Beeck, Bert Frans Sels
  • Publication number: 20180312878
    Abstract: The present application relates to the field of yeast and, specifically, to the identification of yeast alleles that are involved in maximal alcohol accumulation and/or in tolerance to high alcohol levels. The alcohol may be, e.g., ethanol. The identified alleles can be combined or stacked with each other to construe and/or select high alcohol tolerant yeasts, most notably Saccharomyces species.
    Type: Application
    Filed: September 2, 2016
    Publication date: November 1, 2018
    Applicants: VIB VZW, K.U. Leuven Research & Development
    Inventors: Kevin Verstrepen, Yudi Yang, Veerle Saels, Karin Voordeckers, Beatriz Herrera
  • Patent number: 9522932
    Abstract: The invention is directed to a process for the preparation of substituted threonolactone and substituted threose compounds which are intermediates in the synthesis of phosphonate nucleosides being useful antiviral agents.
    Type: Grant
    Filed: September 28, 2015
    Date of Patent: December 20, 2016
    Assignee: K.U. Leuven Research & Development
    Inventors: Piet Herdewijn, Christophe Pannecouque, Tongfei Wu, Erik De Clercq
  • Patent number: 9427447
    Abstract: A compound for use in the treatment or prophylaxis of viral infections such, for example as chicken pox or shingles caused by the Varicella Zoster virus, said compound having the general formula (II): wherein X is O, S, NH or CH2, Y is O, S or NH, Z is O, S or CH2, R1 is C1-6 alkyl, preferably n-alkyl, e.g., n-pentyl or n-hexyl, and one of R2 and R3 is OH, and the other of R3 and R2 is a neutral, non-polar amino acid moiety, or a pharmaceutically acceptable salt or hydrate thereof. Said neutral, non-polar amino acid moiety R2 or R3 may be (IV): in which R4, R5, R6 and R7 are each independently H or C1-2 alkyl. In preferred embodiments, one of R2 or R3 is valine, leucine, isoleucine or alanine, particularly valine.
    Type: Grant
    Filed: September 10, 2014
    Date of Patent: August 30, 2016
    Assignees: University College Cardiff Consultants Limited, K.U. Leuven Research and Development
    Inventors: Christopher McGuigan, Jan Balzarini, Marco Migliore
  • Patent number: 9249177
    Abstract: The invention is directed to processes of preparing phosphonate nucleosides comprising a phosphonalkoxy-substituted five-membered, saturated or unsaturated, oxygen-containing ring coupled to a heterocyclic nucleobase such as a pyrimidine or purine base.
    Type: Grant
    Filed: June 27, 2014
    Date of Patent: February 2, 2016
    Assignee: K.U. Leuven Research & Development
    Inventors: Piet Herdewijn, Christophe Pannecouque, Tongfei Wu, Erik De Clercq
  • Patent number: 9242983
    Abstract: Pyrrolo[2,3-c]pyridine or pyrrolo[3,2-c]pyridine compounds having the general formula (A), wherein the dashed lines, X, Y and R1 through R5 are as defined in the specification. The compounds are useful in the prophylaxis or treatment of viral infections.
    Type: Grant
    Filed: April 8, 2014
    Date of Patent: January 26, 2016
    Assignees: K.U. Leuven Research & Development
    Inventors: Steven S. Bondy, David A. Oare, Gerhard Puerstinger
  • Patent number: 8884011
    Abstract: This invention relates to a purine or pyrimidine phosphonate compound of formula (I) or pharmaceutically acceptable salt thereof; wherein B, X, and R1-R3 are as defined in classes and subclasses herein. These compounds may be used as antiviral precursors. The invention also relates to therapeutic compositions of these compounds and their use for the preparation of a medication for testing and/or preventing a viral infection in a patient. The invention also provides methods for making these compounds. In particular, the invention provides an H-phosphinate precursor intermediate of formula (II) wherein B is a purine or pyrimidine base as defined herein and R1 is selected from the group comprising a hydrogen atom, and a methyl, ethyl, hydroxymethyl, hydroxyethyl and C1-6haloalkyl group.
    Type: Grant
    Filed: November 8, 2007
    Date of Patent: November 11, 2014
    Assignees: Centre National de la Recherche Scientifique-CNRS, Universite d'Aix-Marseille, K.U. Leuven Research & Development
    Inventors: Bruno Canard, Karine Alvarez, Karine Barral, Jean-Louis Romette, Johan Neyts, Jan Balzarini
  • Patent number: 8859512
    Abstract: A compound for use in the treatment or prophylaxis of viral infections such, for example as chicken pox or shingles caused by the Varicella Zoster virus, said compound having the general formula (II): wherein X is O, S, NH or CH2, Y is O, S or NH, Z is O, S or CH2, R1 is C1-6 alkyl, preferably n-alkyl, e.g., n-pentyl or n-hexyl, and one of R2 and R3 is OH, and the other of R3 and R2 is a neutral, non-polar amino acid moiety, or a pharmaceutically acceptable salt or hydrate thereof. Said neutral, non-polar amino acid moiety R2 or R3 may be (IV): in which R4, R5, R6 and R7 are each independently H or C1-2 alkyl. In preferred embodiments, one of R2 or R3 is valine, leucine, isoleucine or alanine, particularly valine.
    Type: Grant
    Filed: November 30, 2012
    Date of Patent: October 14, 2014
    Assignees: University College Cardiff Consultants Limited, K.U. Leuven Research and Development
    Inventors: Christopher McGuigan, Jan Balzarini, Marco Migliore
  • Patent number: 8809520
    Abstract: The invention is directed to processes of preparing phosphonate nucleosides comprising a phosphonalkoxy-substituted five-membered, saturated or unsaturated, oxygen-containing ring coupled to a heterocyclic nucleobase such as a pyrimidine or purine base.
    Type: Grant
    Filed: July 11, 2013
    Date of Patent: August 19, 2014
    Assignee: K.U. Leuven Research & Development
    Inventors: Piet Herdewijn, Christophe Pannecouque, Tongfei Wu, Erik De Clercq
  • Patent number: 8795806
    Abstract: A half closed thermoplastic folded honeycomb structure is described which is produced from a continuous web of material by plastic deformation perpendicular to the plane of the material to thereby form half-hexagonal cell walls and small connecting areas. By folding in the direction of conveyance the cell walls meet to thereby form the honeycomb structure.
    Type: Grant
    Filed: November 21, 2005
    Date of Patent: August 5, 2014
    Assignees: K.U. Leuven Research & Development, Jochen Pflug
    Inventors: Jochen Pflug, Ignace Verpoest
  • Patent number: 8790697
    Abstract: The invention provides a controlled release delivery system comprising a bio-active compound and a matrix carrier, wherein said matrix carrier is an amorphous microporous non-fibrous silicon or titanium oxide being loaded with said bio-active compound and wherein the micropores of said matrix carrier have a mean size in the range of 0.4 to 2.0 nm.
    Type: Grant
    Filed: September 9, 2005
    Date of Patent: July 29, 2014
    Assignee: K.U. Leuven Research & Development
    Inventors: Johan Martens, Guy Van Den Mooter, Jan Van Humbeeck, Caroline Aerts, Randy Mellaerts
  • Patent number: 8779141
    Abstract: The present invention relates to imidazo[4,5-c]pyridine compounds and pharmaceutical compositions for the treatment or prevention of viral infections, wherein the imidazo[4,5-c]pyridine compounds have the formula:
    Type: Grant
    Filed: May 19, 2009
    Date of Patent: July 15, 2014
    Assignees: Gilead Sciences, Inc., K.U. Leuven Research & Development, Gerhard Puerstinger
    Inventors: Johan Neyts, Gerhard Pürstinger, Erik De Clercq
  • Patent number: 8722677
    Abstract: Pyrrolo[2,3-c]pyridine or pyrrolo[3,2-c]pyridine compounds having the general formula (A), wherein the dashed lines, X, Y and R1 through R5 are as defined in the specification. The compounds are useful in the prophylaxis or treatment of viral infections.
    Type: Grant
    Filed: June 22, 2012
    Date of Patent: May 13, 2014
    Assignees: Gilead Sciences, Inc., K.U. Leuven Research & Development
    Inventors: Steven S. Bondy, David A. Oare, Gerhard Puerstinger
  • Patent number: 8670619
    Abstract: A method for operating on images is described for interest point detection and/or description working under different scales and with different rotations, e.g. for scale-invariant and rotation-invariant interest point detection and/or description.
    Type: Grant
    Filed: April 17, 2012
    Date of Patent: March 11, 2014
    Assignees: Toyota Motor Europe NV, K.U. Leuven Research & Development, Eidgenoessische Technische Hochschule Zurich
    Inventors: Ryuji Funayama, Hiromichi Yanagihara, Luc Van Gool, Tinne Tuytelaars, Herbert Bay
  • Patent number: 8658616
    Abstract: Compounds having the general formula (I): are provided which have enhanced inhibitory potency and are thus useful in methods of prophylaxis or treatment of a viral infection such as hepatitis C virus. The compounds are phosphoramidate derivatives of nucleoside compounds derived from bases such as adenine and guanine. The glycoside moiety of the nucleoside compound can be substituted at the ss-2? position with methyl and the phosphoramidate group can be 1-naphthyl linked by —O— to the P atom. These compounds can be administered as pharmaceutical compositions, and methods for their preparation are also provided.
    Type: Grant
    Filed: November 23, 2007
    Date of Patent: February 25, 2014
    Assignees: University College Cardiff Consultants Limited, K.U. Leuven Research and Development
    Inventors: Christopher McGuigan, Plinio Perrone, Johan Neyts
  • Patent number: 8569487
    Abstract: A compound of formula (1) and its salts and solvates are provided for the treatment or prophylaxis of hepatitis C virus infections. Methods of making and formulating compound (1) are provided.
    Type: Grant
    Filed: July 6, 2007
    Date of Patent: October 29, 2013
    Assignees: Gilead Sciences, Inc., K.U. Leuven Research & Development
    Inventors: Steven S. Bondy, Terrence C. Dahl, David A. Oare, Reza Oliyai, Winston C. Tse, Vahid Zia
  • Patent number: 8569488
    Abstract: A crystalline compound of formula (1) and its salts and solvates are provided for the treatment or prophylaxis of hepatitis C virus infections Methods of making and formulating crystalline compound (1) are provided.
    Type: Grant
    Filed: December 23, 2011
    Date of Patent: October 29, 2013
    Assignees: Gilead Sciences, Inc., K.U. Leuven Research & Development
    Inventors: Eric D. Dowdy, Kenneth M. Kent, Norma J. Tom, Vahid Zia
  • Patent number: 8501709
    Abstract: The invention is directed to phosphonate nucleosides comprising a phosphonalkoxy-substituted five-membered, saturated or unsaturated, oxygen-containing ring coupled to a heterocyclic nucleobase such as a pyrimidine or purine base, as well as pharmaceutical compositions thereof. These compounds, which can be described by general formula (II), are useful for the treatment of retroviral infection, e.g., HIV (Human Immunodeficiency Virus) infection in a mammal. The invention also features synthetic intermediates for the preparation of phosphonate nucleosides.
    Type: Grant
    Filed: November 8, 2011
    Date of Patent: August 6, 2013
    Assignee: K.U.Leuven Research & Development
    Inventors: Piet Herdewijn, Christophe Pannecouque, Tongfei Wu, Erik De Clercq
  • Patent number: 8470826
    Abstract: The present invention relates to an episomal structure expressing a functional oncogene, whereby said oncogene is a fusion gene of two chromosomal gene fragments. More specifically, the invention relates to a NUP214-ABL1 fusion product, important in the development of T-cell acute lymphoblastic leukemia, to methods to detect the fusion and to methods to prevent the oncogenic activity of said fusion product.
    Type: Grant
    Filed: June 15, 2010
    Date of Patent: June 25, 2013
    Assignees: VIB VZW, K.U. Leuven Research and Development
    Inventors: Jan Cools, Anne Hagemeijer, Peter Marynen
  • Patent number: 8450318
    Abstract: Molecules having a spacer unit, linker and recognition unit(s) are used for the treatment of various diseases, disorders and conditions. The compounds are useful in treating infectious diseases and diseases, disorders or conditions related thereto. Further, the methods for treating diseases, disorders or conditions involve recognition and binding of carbohydrate structures.
    Type: Grant
    Filed: March 18, 2008
    Date of Patent: May 28, 2013
    Assignees: K.U. Leuven Research and Development
    Inventors: Monika Mazik, Jan Balzarini